Skip to main content
HALO logo

HALO · Halozyme Therapeutics, Inc. · Analyst Estimates

Track HALO — free
$110.00 -1.56 (-1.40%) At close · Sep 30
Market Cap
$12.93B
Shares
113.50M
Volume · Sep 30 3.56M Avg daily vol (3M) 2.14M

Analyst Estimates

Compare analyst forecasts for Halozyme Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-09-18 19:26 UTC · Publication dates shown per estimate · 16 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
7.91
8.57694
8.9
—
8.57694
8.1613
8.57694
8.1613
— — — —
EPS
analysts
Publication date not stated
— — —
6
— — — —
1
0
2
2
Revenue
USD
Publication date not stated
1757000000
1853593910
1909200000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
8
— — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
10.0
10.39306
11.01
—
10.39306
9.89267
10.39306
9.89267
— — — —
EPS
analysts
Publication date not stated
— — —
5
— — — —
1
0
3
3
Revenue
USD
Publication date not stated
1862000000
2050296910
2224600000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
8
— — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
2.1452
2.29087
2.37
—
2.29087
2.18928
2.29087
2.18928
— — — —
EPS
analysts
Publication date not stated
— — —
6
— — — —
1
0
2
2
Revenue
USD
Publication date not stated
458000000
484321170
495000000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
6
— — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
2.43
2.59104
2.67
—
2.59104
2.57843
2.59104
2.57843
— — — —
EPS
analysts
Publication date not stated
— — —
6
— — — —
1
0
2
2
Revenue
USD
Publication date not stated
527000000
537859500
561400000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
6
— — — — — — — —
Key facts CIK 1159036 CUSIP 40637H109 13F (30d) 21 filings 16 filers Visit website Investor relations